Royal Bank Of Canada Has Lowered Expectations for BeOne Medicines (NASDAQ:ONC) Stock Price

BeOne Medicines (NASDAQ:ONC) had its target price lowered by research analysts at Royal Bank Of Canada from $451.00 to $450.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 37.79% from the stock’s previous close.

Several other research firms have also recently issued reports on ONC. Nomura upgraded BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Truist Financial upped their target price on shares of BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a research report on Thursday. Guggenheim boosted their price target on shares of BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $395.85.

BeOne Medicines Stock Performance

Shares of ONC traded down $0.95 during trading hours on Thursday, hitting $326.58. The stock had a trading volume of 149,475 shares, compared to its average volume of 279,843. The firm has a market capitalization of $35.83 billion, a PE ratio of 73.06 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines has a 12 month low of $253.95 and a 12 month high of $385.22. The stock has a fifty day moving average price of $294.53 and a 200 day moving average price of $308.67.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Analysts anticipate that BeOne Medicines will post 5.93 EPS for the current year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, CFO Aaron Rosenberg sold 1,157 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $312.71, for a total transaction of $361,805.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 61,397 shares of the stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $317.67, for a total value of $19,503,984.99. Following the completion of the sale, the chief executive officer owned 9,180 shares in the company, valued at approximately $2,916,210.60. The trade was a 86.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 345,561 shares of company stock valued at $105,625,947 in the last 90 days. Corporate insiders own 6.19% of the company’s stock.

Institutional Trading of BeOne Medicines

A number of large investors have recently made changes to their positions in ONC. BNP Paribas Financial Markets boosted its stake in shares of BeOne Medicines by 100.6% in the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after buying an additional 97,244 shares in the last quarter. SEB Asset Management AB acquired a new position in shares of BeOne Medicines during the 1st quarter worth $16,653,000. Renaissance Technologies LLC purchased a new position in shares of BeOne Medicines in the 1st quarter valued at about $19,438,000. Capital International Sarl lifted its stake in shares of BeOne Medicines by 2.7% in the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares during the period. Finally, Slow Capital Inc. boosted its holdings in BeOne Medicines by 51.5% during the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after buying an additional 9,280 shares in the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines News Roundup

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 results exceeded expectations: BeOne reported earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. Revenue reportedly surged 30% year over year, signaling strong commercial momentum. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook was raised: Management now expects fiscal-year revenue of $6.6 billion to $6.8 billion, above the $6.5 billion Wall Street forecast. The higher outlook suggests confidence in demand for BeOne’s marketed cancer treatments. BeOne raises 2026 outlook
• Positive Sentiment: Analysts raised targets: Guggenheim lifted its price target from $420 to $430 and assigned a Buy rating, while Citizens JMP raised its target from $396 to $405 and maintained a Market Outperform rating. The revisions reflect stronger earnings and growth expectations. Analyst price-target updates
• Positive Sentiment: Pipeline development advanced: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially supporting faster regulatory engagement and development of the candidate. UK Innovation Passport announcement
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at approximately $362,000 to cover tax withholding associated with vested equity awards. Because the transaction was not described as discretionary, it is a limited bearish signal. SEC insider transaction filing
• Neutral Sentiment: Valuation remains demanding: Despite improving fundamentals and a generally favorable analyst view, ONC trades at a relatively high earnings multiple, leaving the stock sensitive to any slowdown in growth or disappointing pipeline news.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.